Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | GEMSTONE-301: sugemalimab versus placebo for phase III NSCLC

Yi-Long Wu, MD, FACS, Guangdong General Hospital, Guangzhou, China, gives an overview of the rationale, design and results of the randomized, double-blind, placebo-controlled Phase III GEMSTONE-301 clinical trial (NCT03728556) evaluating sugemalimab, an anti-PD-L1 monoclonal antibody, as a consolidation treatment in patients with stage III non-small cell lung cancer (NSCLC) who have not progressed on concurrent or sequential chemoradiotherapy (CRT). Concurrent CRT is the current standard of care for patients with unresectable stage III NSCLC. Nevertheless, up to 50% of patients cannot tolerate this treatment and they are therefore given sequential CRT. The study met its primary endpoint of progression-free survival (PFS) and there was a trend towards a benefit in overall survival (OS) for patients receiving sugemalimab. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.


Dr Wu reports advisory services for AstraZeneca, Boehringer Ingelheim, Novartis, Takeda; personal fees from AstraZeneca, Beigene, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, Sanofi; grants from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, and Roche, outside the submitted work.